Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans

Response to “Can CYP3A Activity Be Evaluated for Drug Interaction Using a Nanogram Dose of Probe Drug?”: Evaluation of CYP3A Activity With Microdoses of Midazolam

(2014) N Hohmann et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Deceptive argumentation against diagnostic microdosing of anticancer drugs

(2014) Dirk Theile et al.   INTERNATIONAL JOURNAL OF CANCER

Cytochrome P450-3A Phenotyping Using Midazolam Is Not Altered by OATP1B1 Polymorphisms

(2013) V C Ziesenitz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions

(2013) B Halama et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1′-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry

(2012) Jürgen Burhenne et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Predicting Drug Candidate Victims of Drug-Drug Interactions, using Microdosing

(2012) Marie Croft et al.   CLINICAL PHARMACOKINETICS

Metabolism of 1'- and 4-Hydroxymidazolam by Glucuronide Conjugation Is Largely Mediated by UDP-Glucuronosyltransferases 1A4, 2B4, and 2B7

(2010) K.-A. Seo et al.   DRUG METABOLISM AND DISPOSITION

Effect of Simultaneous Induction and Inhibition of CYP3A by St John's Wort and Ritonavir on CYP3A Activity

(2009) V Hafner et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS